BR0100946A - Metabólitos de hexahidropirazolo[4,3-c] piridina - Google Patents
Metabólitos de hexahidropirazolo[4,3-c] piridinaInfo
- Publication number
- BR0100946A BR0100946A BR0100946-0A BR0100946A BR0100946A BR 0100946 A BR0100946 A BR 0100946A BR 0100946 A BR0100946 A BR 0100946A BR 0100946 A BR0100946 A BR 0100946A
- Authority
- BR
- Brazil
- Prior art keywords
- metabolites
- oxo
- benzyl
- racemic
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Patente de Invenção: "METABóLITOS DEHEXAHIDROPIRAZOLO[4,3C] PIRIDINA". A invençãoproporciona metabólitos do composto2-amino-N-[2(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pirazolo-[4,3-c] piridin-5il)-1-(R)-benzil-oximetil-2-oxo-etil]-isobutiramida, asmisturas racêmicasdiastereoméricas e isómeros ópticos destes, assuas pró-drogas e os sais farmaceuticamente aceitáveis dosmetabólitos, misturas racêmicasdiastereoméricas, isómeros ópticose pró-drogas; composições farmacêuticas destes; e métodos deutilizar os metabólitos e as formulações no tratamento de doençasrelacionadas com níveis reduzidos do hormónio do crescimento. Ainvenção proporciona ainda um kit compreendendo um metabólitodo composto2-amino-N-[2-(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7hexahidro-pirazolo-[4,3-c]piridin-5-il)-1 -(R)-benzil-oximetil-2-oxo-etíl]-isobutiramida,uma mistura racêmica-diastereomérica ou um isómero óptico deste,uma sua pró-droga ou um sal farmaceuticamente aceitável dometabólito, mistura racómica-diastereamérica, isómero óptico oupró-droga e um excipiente, veículo ou diluente farmaceuticamenteaceitável em uma primeira forma de dosagem; estrogênio,progesterona Premarin<32>, ou um bisfosfonato, preferencialmentealendronato, e um excipiente, veículo ou diluentefarmaceuticamente aceitável em uma segunda forma de dosagem;e uma embalagem.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18796500P | 2000-03-09 | 2000-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0100946A true BR0100946A (pt) | 2001-10-30 |
Family
ID=22691219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0100946-0A BR0100946A (pt) | 2000-03-09 | 2001-03-09 | Metabólitos de hexahidropirazolo[4,3-c] piridina |
Country Status (5)
Country | Link |
---|---|
US (1) | US6531449B2 (pt) |
EP (1) | EP1132388A3 (pt) |
JP (1) | JP3529736B2 (pt) |
BR (1) | BR0100946A (pt) |
CA (1) | CA2339528C (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020165816A1 (en) * | 2001-05-02 | 2002-11-07 | Barz Graydon Lee | Method for stochastically modeling electricity prices |
WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
EP1907066A4 (en) * | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | SYSTEM AND METHOD FOR THE ADMINISTRATION OF RADIATION THERAPY IN A POTENTIAL INTEREST |
US7639854B2 (en) * | 2005-07-22 | 2009-12-29 | Tomotherapy Incorporated | Method and system for processing data relating to a radiation therapy treatment plan |
EP1906827A4 (en) * | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | SYSTEM AND METHOD FOR EVALUATING THE DOSE USED BY A RADIATION THERAPY SYSTEM |
JP2009502257A (ja) * | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | デリバーされた線量を評価するための方法およびシステム |
EP1907968A4 (en) | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | METHOD AND SYSTEM FOR EVALUATING QUALITY ASSURANCE CRITERIA FOR A TREATMENT ADMINISTRATION PROGRAM |
ATE507879T1 (de) * | 2005-07-22 | 2011-05-15 | Tomotherapy Inc | System zur verabreichung einer strahlentherapie auf ein sich bewegendes zielgebiet |
US7574251B2 (en) * | 2005-07-22 | 2009-08-11 | Tomotherapy Incorporated | Method and system for adapting a radiation therapy treatment plan based on a biological model |
JP2009507524A (ja) * | 2005-07-22 | 2009-02-26 | トモセラピー・インコーポレーテッド | 変形マップに制約を課す方法およびそれを実装するためのシステム |
US20070195922A1 (en) * | 2005-07-22 | 2007-08-23 | Mackie Thomas R | System and method of monitoring the operation of a medical device |
AU2006272821A1 (en) | 2005-07-23 | 2007-02-01 | Tomotherapy Incorporated | Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch |
CN105027227B (zh) | 2013-02-26 | 2017-09-08 | 安科锐公司 | 电磁致动的多叶准直器 |
WO2015053023A1 (ja) * | 2013-10-08 | 2015-04-16 | シャープ株式会社 | 画像表示装置 |
RU2695649C2 (ru) * | 2014-08-05 | 2019-07-25 | Раквалиа Фарма Инк. | Производные серина в качестве агонистов грелиновых рецепторов |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
UA64751C2 (uk) * | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
US6541634B2 (en) * | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
-
2001
- 2001-03-06 EP EP01302043A patent/EP1132388A3/en not_active Withdrawn
- 2001-03-07 CA CA002339528A patent/CA2339528C/en not_active Expired - Fee Related
- 2001-03-08 US US09/801,964 patent/US6531449B2/en not_active Expired - Fee Related
- 2001-03-09 BR BR0100946-0A patent/BR0100946A/pt not_active IP Right Cessation
- 2001-03-09 JP JP2001066202A patent/JP3529736B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2339528C (en) | 2007-05-08 |
JP2001278866A (ja) | 2001-10-10 |
EP1132388A2 (en) | 2001-09-12 |
US20020002138A1 (en) | 2002-01-03 |
JP3529736B2 (ja) | 2004-05-24 |
US6531449B2 (en) | 2003-03-11 |
CA2339528A1 (en) | 2001-09-09 |
EP1132388A3 (en) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0100946A (pt) | Metabólitos de hexahidropirazolo[4,3-c] piridina | |
NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
WO2005102381A1 (ja) | カテプシンk阻害薬およびpth類を併用することを特徴とする骨密度増加剤 | |
WO2002015903A3 (de) | Neue pharmazeutische zusammensetzung zur verabreichung von n-0923 | |
EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
WO2007050726A3 (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
NO20061702L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist | |
SV2002000440A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb | |
CA2360313A1 (en) | Glucocorticoid receptor modulators | |
YU37203A (sh) | Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti | |
CA2442478A1 (en) | Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation | |
CA2360308A1 (en) | Glucocorticoid receptor modulators | |
WO2005002582A3 (en) | Trp-p8 active compounds and therapeutic treatment methods | |
AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
HUP0100024A2 (hu) | Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények | |
DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
ES2271229T3 (es) | Uso de antagonistas mglur5 para el tratamiento de condiciones pruriticas. | |
JP6377620B2 (ja) | グルコース取り込みを改善するための組成物および方法 | |
AP1530A (en) | Pharmaceutical composition for intramuscular injection containing loxoprofen. | |
KR20030027007A (ko) | 엔도텔린 길항제를 사용하여 암 및 이와 관련된 통증을치료하는 방법 | |
WO2005065372A3 (en) | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |